Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 2/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | AGXT | P21549 | 2/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6885649 | 0.79 | PSEN1 (0.37) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6549228 | 0.79 | PSEN1 (0.37) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL22006160 | 0.76 | REN (0.44) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL17803300 | 0.76 | REN (0.44) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6550961 | 0.74 | TACR1 (0.34) | RENSIGMAR1TACR1 | |
| SCHEMBL24597253 | 0.72 | IDO1 (0.50) | RENKCNA5IDO1AGXTNAAA | |
| SCHEMBL6885891 | 0.71 | METAP2 (0.40) | RENKCNA5TACR1IDO1AGXT | |
| SCHEMBL13103437 | 0.70 | KCNA5 (0.47) | RENKCNA5SIGMAR1TACR1IDO1 | |
| SCHEMBL6885058 | 0.69 | IDO1 (0.38) | RENIDO1AGXTNAAAAPP | |
| SCHEMBL15032473 | 0.69 | NAAA (0.46) | SIGMAR1TACR1MAPK1IDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480964-A1 | INHIBITEURS DE L'ANGIOGENESE | Galderma Research & Development, S.N.C. (FR) | 2004-12-01 | — | — | EP | disclosed |
| US-6803382-B2 | 1-OXASPIRO(2,5)OCTAN-6-OL DERIVATIVES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-10-12 | — | — | US | disclosed |
| US-20030134896-A1 | Novel angiogenesis inhibitors and pharmaceutical and cosmetic use thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-07-17 | — | — | US | disclosed |
| WO-2003040119-A1 | ANGIOGENESIS INHIBITORS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134896-A1 | Novel angiogenesis inhibitors and pharmaceutical and cosmetic use thereof | VEGFA, KDR, FLT1 | REN 2405/4885PSEN1 1915/4885PSEN2 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.